Silicon Valley Capital Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Silicon Valley Capital Partners’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$373	Hold	30	–	–	﹤0.01%	375
2025 Q4	$378	Hold	30	–	–	﹤0.01%	257
2025 Q3	$300	Hold	30	–	–	﹤0.01%	273
2025 Q2	$243	Hold	30	–	–	﹤0.01%	298
2025 Q1	$248	Hold	30	–	–	﹤0.01%	238
2024 Q4	$238	Hold	30	–	–	﹤0.01%	305
2024 Q3	$250	Hold	30	–	–	﹤0.01%	300
2024 Q2	$191	Hold	30	–	–	﹤0.01%	299
2024 Q1	$182	Hold	30	–	–	﹤0.01%	294
2023 Q4	$182	Hold	30	–	–	﹤0.01%	323
2023 Q3	$127	Hold	30	–	–	﹤0.01%	280
2023 Q2	$93	Hold	30	–	–	﹤0.01%	296
2023 Q1	$42	Hold	30	–	–	﹤0.01%	248
2022 Q4	$60	Buy	+30	New	+$67	﹤0.01%	205

Other funds holding AMRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Silicon Valley Capital Partners's AMRX Position: Q1 2026 in Review

Silicon Valley Capital Partners held its Amneal Pharmaceuticals (AMRX) position steady in Q1 2026 at 30 shares worth $373. The position accounts for ﹤0.01% of the portfolio, ranked #375.

Silicon Valley Capital Partners first reported a position in AMRX in Q4 2022 and has held it in 14 quarters since. The position peaked at $378 in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

Silicon Valley Capital Partners held 30 shares of Amneal Pharmaceuticals worth $373 as of Q1 2026.
Silicon Valley Capital Partners left its Amneal Pharmaceuticals share count unchanged in Q1 2026.
Amneal Pharmaceuticals made up ﹤0.01% of Silicon Valley Capital Partners's portfolio in Q1 2026, its #375 holding.
Silicon Valley Capital Partners first reported a position in Amneal Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
Silicon Valley Capital Partners's Amneal Pharmaceuticals position peaked at $378 in Q4 2025.
315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Silicon Valley Capital Partners's 13F filing for Q1 2026, filed 19 May 2026.